Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUCHEC trial of durvalumab and tremelimumab with gemcitabine-based chemotherapy in first-line biliary tract cancer
2017-001538-25Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Nov 2017
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cholangiocarcinoma (CCA), gallbladder cancer and biliary cancer comparing Durvalumab + tremelimumab + gemcitabine, Durvalumab + tremelimumab + gemcitabine + cisplatin and Gemcitabine + cisplatin (3 arms). Primary endpoint: Objective response rate. Started Nov 2017; status: completed.
02
Drugs
durvalumabtremelimumabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on 2017-001538-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001538-25.